Division of General Surgery, Department of Surgery, Linkou Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan.
College of Medicine, Chang Gung University, Guishan, Taoyuan, Taiwan.
Hepatol Int. 2022 Dec;16(6):1353-1367. doi: 10.1007/s12072-022-10422-8. Epub 2022 Sep 28.
In the 8th edition of American Joint Committee on Cancer (AJCC) staging system for hepatocellular carcinoma (HCC), tumor size is not considered in T1 stage. The present study aimed to find out the optimal cutoff for tumor size to further stratify patients with T1 HCC.
Operated HCC patients were identified from the Chang Gung Research Database (CGRD), and the patients with T1bN0M0 tumors were further divided into two groups based on the tumor size. The resulting subgroups were denoted as T1b (≤ cutoff) and T1c (> cutoff). The survivals were compared between T1a/b and T1c as well as T1c and T2.
From 2002 to 2018, a total of 2893 patients who underwent surgery for T1N0M0 HCC were identified from the CGRD. After excluding cases who died within 30 days of surgery, Kaplan-Meier survival analysis discovered that T1 tumors > 65 mm (T1c) had survivals similar to those of T2N0M0 tumors. Cox regression multivariate analysis further demonstrated that tumor size > 6.5 cm was an independent poor prognostic indicator for T1 HCC. Sensitivity tests also confirmed that tumors lager than 6.5 cm were significantly more likely to develop both tumor recurrence and liver-specific death after surgery.
Our study demonstrated that tumor size would significantly impact the survival outcome of T1 HCC after surgery. Due to significantly worse survival, we proposed a subclassification within T1 HCC, T1c: solitary tumor > 6.5 cm without vascular invasion, to further stratify those patients at risk. Further studies are mandatory to validate our findings.
在第八版美国癌症联合委员会(AJCC)肝癌分期系统中,肿瘤大小不再被纳入 T1 期。本研究旨在寻找肿瘤大小的最佳临界值,以进一步对 T1 期肝癌患者进行分层。
从长庚研究数据库(CGRD)中确定接受手术治疗的肝癌患者,并根据肿瘤大小将 T1bN0M0 肿瘤患者进一步分为两组。将这两个亚组分别命名为 T1b(≤临界值)和 T1c(>临界值)。比较 T1a/b 与 T1c 以及 T1c 与 T2 之间的生存情况。
2002 年至 2018 年,从 CGRD 中确定了 2893 例接受 T1N0M0 肝癌手术治疗的患者。排除术后 30 天内死亡的病例后,Kaplan-Meier 生存分析发现 T1 肿瘤>65mm(T1c)的患者生存情况与 T2N0M0 肿瘤相似。Cox 回归多因素分析进一步表明,肿瘤大小>6.5cm 是 T1 肝癌独立的不良预后指标。敏感性测试也证实,手术后肿瘤大于 6.5cm 的患者发生肿瘤复发和肝脏特异性死亡的风险显著增加。
本研究表明,肿瘤大小显著影响 T1 期肝癌患者手术后的生存结果。由于生存情况明显较差,我们建议在 T1 期肝癌中进行亚分类,即 T1c:无血管侵犯的单个肿瘤>6.5cm,以进一步对处于危险中的患者进行分层。需要进一步的研究来验证我们的发现。